Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide, Thalidomide, and Celecoxib in Newly Diagnosed GBM
NCT00047294Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2001
- Primary completion
- Mar 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of temozolomide, thalidomide, celecoxib in glioblastoma multiforme (GBM), sponsored by Dana-Farber Cancer Institute. Started Apr 2001; status: completed.
02
Drugs
temozolomidethalidomidecelecoxib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00047294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00047294.